Figure e-4. Changes in blood CD20 CD8+ T cell subsets upon Ocrelizumab treatment.

Percentages of total (left panels), CD20- (central panels) and CD20+ (right panels) CD8+ T cells subsets, obtained before (0M) and at 6 months (6M) of ocrelizumab treatment (n=39). Percentages are referred to total CD8+ cells. P values were corrected by using Bonferroni test. Abbreviations: CM, Central Memory; EM, Effector Memory; TD, Terminally differentiated.